Zenas BioPharma, Inc. Common Stock (ZBIO) Stock Analysis

Zenas BioPharma, Inc. Common Stock (ZBIO) is a publicly traded company in the HEALTHCARE sector. It trades at $17.13, carries a market capitalization of $1.15B. This page summarizes the public market data, fundamentals, and frequently asked questions for ZBIO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $17.13
• Market Cap: $1.15B
• EPS: $-9.10
• 52-Week High: $44.60
• 52-Week Low: $8.91

Market Sentiment

Zenas BioPharma, Inc. Common Stock currently has a Bullish sentiment score of 0.61.

About Zenas BioPharma, Inc. Common Stock

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, dedicated to developing and commercializing innovative immunology-based therapies. With a strong focus on addressing unmet medical needs, Zenas boasts a robust pipeline aimed at treating autoimmune and rare diseases. The company utilizes proprietary technology platforms to create therapies that enhance immune responses, thereby improving patient outcomes and solidifying its position as...

GNG Research Analysis

GNG Research scores Zenas BioPharma, Inc. Common Stock (ZBIO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ZBIO.

Frequently Asked Questions

Does ZBIO pay dividends?

Zenas BioPharma, Inc. Common Stock (ZBIO) does not currently pay a regular dividend.

What is ZBIO's market cap?

Zenas BioPharma, Inc. Common Stock (ZBIO) has a market capitalization of $1.15B with a current stock price of $17.13.